The gene, found in all complex organisms, including plants and animals, encodes for a large group of enzymes known as protein kinases that enabled cells to be larger and to rapidly transfer information from one part to another.
"If the duplications and subsequent mutations of this gene during evolution did not happen, then life would be completely different today," said Steven Pelech, a Professor at the University of British Columbia in Canada.
Plants, animals, mushrooms and more all exist because they are made up of eukaryotic cells that are larger and far more complex than bacteria.
Inside of these eukaryotic cells are hundreds of organelles that perform diverse functions to keep them living, just as different organs do for the human body.
The new research identified the gene that gave rise to protein kinases.
On a cellular scale, these highly interactive signalling proteins play a role similar to the neurons in the brain by transferring information throughout the cell by a process known as protein phosphorylation.
Research into these enzymes has become very important to medicine. More than 400 human diseases like cancer and diabetes are linked to problems with cell signalling. Disease occurs when a cell gets misinformed or confused.
Today about one-third of all pharmaceutical drug development is targeted at protein kinases, researchers said.
For more than 30 years, researchers have known that most protein kinases came from a common ancestor because their genes are so similar.
"Our new research revealed that the gene probably originated from bacteria for facilitating the synthesis of proteins and then mutated to acquire completely new functions," said Pelech.
The same gene that gave rise to protein kinases also led to the formation of a group of enzymes know as choline and ethanolamine kinases.
The choline kinase enzyme is critical for the production of phosphatidylcholine, a major component of the membranes that wrap around eukaryotic cells and their organelles, but is missing from bacteria.
this a hark back to the days of eugenics, the idea of the superior Aryan propagated in Nazi-era Germany?
Here, Mukherjee says, there are three broad guidelines which must govern our decision. The diseases that we are talking about should involve "extraordinary suffering". An example would be a cognitive intellectual malady like down syndrome. What falls within the purview of this "extraordinary suffering" is a decision for society to make.
The second question to be considered is if one has the gene, what is the chance of getting the disease?
At the same time, he writes, "these parameters are inherently susceptible to the logic of self reinforcement."
"We determine the definition of extraordinary suffering. We demarcate the boundaries of normalcy vs abnormalcy. We make the medical choices to intervene. We determine the nature of justifiable and non-justifiable interventions," he writes in the book.
In the midst of all these questions, lies the tale of Mukherjee's own family -- of two uncles and a cousin suffering from schizophrenia and bipolar disorder. The connection between the tale of the gene and the fear of contracting the hereditary malady is unmistakable.
The advances being made in genetic manipulation are rapid. But the answers to the ethical dilemmas are not so easily forthcoming.
With huge strides being made in this field everyday, the need of the hour is for a comprehensive international legal framework so that genetic engineering does not devolve into a free-for-all "arms race" among the countries of the world, Mukherjee says.
The author was in the capital recently to launch his book.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
